Physician profile
David Oliver
NPI 1265424733
$4,482.22
in general payments reported to CMS, 2019-2025
34 companies · $956 in 2025
The $956 reported for 2025 was more than what 87% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,019 · 2020: $233 · 2021: $198 · 2022: $410 · 2023: $757 · 2024: $909 · 2025: $956.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,522 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,522.33 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $807.60 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals Lp | $663.88 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Genzyme Corporation | $487.07 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $387.07 | 2019-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Mallinckrodt Hospital Products INC. | $338.32 | 2021-2025 | Acthar |
| Takeda Pharmaceuticals U.S.A., INC. | $241.80 | 2020-2025 | Glassia |
| Harmony Biosciences LLC | $228.23 | 2023-2024 | Wakix |
| Insmed, INC. | $192.58 | 2019-2025 | Arikayce |
| Mylan Specialty L.P. | $118.67 | 2019-2023 | Yupelri |
| Baxter Healthcare | $107.31 | 2024-2025 | Hillrom - Vest System Model 105 Home Care |
| Novartis Pharmaceuticals Corporation | $92.89 | 2019-2024 | |
| Amgen INC. | $77.70 | 2022-2025 | Tezspire |
| Sanofi-Aventis U.S. LLC | $76.99 | 2022 | |
| Mallinckrodt Enterprises LLC | $64.43 | 2019 | |
| Merck Sharp & Dohme LLC | $55.26 | 2019-2025 | Keytruda |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $53.57 | 2019-2021 | |
| Axsome Therapeutics, INC. | $48.41 | 2024-2025 | Sunosi |
| Verona Pharma, INC. | $44.03 | 2025 | Ohtuvayre |
| Vifor Pharma, INC. | $43.80 | 2024-2025 | Zemaira |
| Philips North America LLC | $42.81 | 2019-2022 | |
| United Therapeutics Corporation | $36.89 | 2019 | |
| Optinose US, INC. | $29.60 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $28.87 | 2019 | |
| Csl Behring | $24.46 | 2020 | |
| Irhythm Technologies, INC. | $24.39 | 2021 | |
| Viatris Specialty LLC | $24.33 | 2025 | Yupelri |
| Allergan, INC. | $21.76 | 2019 | |
| Pharming Healthcare, INC. | $20.17 | 2024 | Ruconest |
| E.R. Squibb & Sons, L.L.C. | $18.57 | 2020 | |
| Grifols USA, LLC | $18.50 | 2019 | |
| Shire North American Group INC | $18.10 | 2019 | |
| Resmed Corp | $16.28 | 2019 | |
| Jazz Pharmaceuticals INC. | $15.26 | 2020 | |
| Novo Nordisk INC | $12.62 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Oliver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.